Insmed Growth Agent iPlex Joins Tercica's Increlex With Orphan Drug Designation
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves iPlex for the same indication as Increlex, but both products are granted orphan drug exclusivity.
You may also be interested in...
Insmed Growth Treatment iPlex Enters Market
Mecasermin rinfabate injection will compete with Tercica’s Increlex.
Insmed Growth Treatment iPlex Enters Market
Mecasermin rinfabate injection will compete with Tercica’s Increlex.
Tercica’s Growth Treatment Increlex Clears FDA With Orphan Drug Exclusivity
The company plans to launch the extreme short stature therapy in January with a 30-member sales force.